Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506347 | 0.85 | LMNA (0.59) | CYP1A2KDM4EAGTR1LMNA | |
| SCHEMBL7506353 | 0.85 | LMNA (0.59) | CYP1A2KDM4EAGTR1LMNA | |
| SCHEMBL30480678 | 0.83 | CYP3A4 (0.41) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL28177618 | 0.83 | CYP3A4 (0.41) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL27486127 | 0.82 | ALDH1A1 (0.50) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL1773434 | 0.80 | CYP1A2 (0.39) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL1491279 | 0.79 | INPPL1 (0.44) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL28192016 | 0.79 | SLC6A2 (0.47) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL16797585 | 0.79 | HTR1A (0.56) | KDM4ELMNAMEN1KMT2A | |
| SCHEMBL16809470 | 0.78 | CYP1A2 (0.47) | CYP1A2KDM4EAGTR1LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854751-B1 | USE OF N-METHYL-N-ACYLGLUCAMINES AS SOLUBILIZERS | CLARIANT INT LTD (CH) | 2016-08-10 | — | — | EP | claimed |
| EP-1339792-B1 | SURFACTANT-CONTAINING COSMETIC, DERMATOLOGICAL AND PHARMACEUTICAL AGENTS | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2015-02-25 | — | — | EP | claimed |
| EP-2297060-B1 | RHEOLOGY INFLUENCING ADDITIVE FOR MINERAL BUILDING MATERIALS | AKZO NOBEL NV (NL) | 2013-10-09 | — | — | EP | claimed |
| CN-102007084-B | Rheology influencing additive for mineral building materials | AKZO NOBEL NV | 2013-10-09 | — | — | CN | claimed |
| EP-2634152-A1 | Rheology influencing additive for mineral building materials | Akzo Nobel N.V. (NL) | 2013-09-04 | — | — | EP | claimed |
| US-8187581-B2 | Copolymers from acryloyldimethyltaurine or an acryloyldimethyltaurate, olefinically unsaturated, noncationic, crosslinking comonomer, olefinically unsaturated, cationic comonomer having oxygen, nitrogen, sulfur or phosphorus, silicon-containing component, macromonomer having oxygen, nitrogen, sulfur | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| CN-102007084-A | Rheology influencing additive for mineral building materials | AKZO NOBEL NV | 2011-04-06 | — | — | CN | claimed |
| EP-2297060-A1 | RHEOLOGY INFLUENCING ADDITIVE FOR MINERAL BUILDING MATERIALS | Akzo Nobel N.V. (NL) | 2011-03-23 | — | — | EP | claimed |
| US-20110039984-A1 | RHEOLOGY INFLUENCING ADDITIVE FOR MINERAL BUILDING MATERIALS | AKZO NOBEL N.V. (NL) | 2011-02-17 | — | — | US | claimed |
| WO-2009144081-A1 | RHEOLOGY INFLUENCING ADDITIVE FOR MINERAL BUILDING MATERIALS | AKZO NOBEL N.V. (NL) | 2009-12-03 | — | — | WO | claimed |
| US-20080107617-A1 | Surfactant-containing cosmetic, dermatological and pharmaceutical agents | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH | 2008-05-08 | — | — | US | claimed |
| US-7332155-B2 | Surfactant-containing cosmetic, dermatological and pharmaceutical agents | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2008-02-19 | — | — | US | claimed |
| US-6946139-B2 | Methods for producing foam from multiphase compositions | CLARIANT GMBH (DE) | 2005-09-20 | — | — | US | claimed |
| US-20040141937-A1 | comprising comb copolymers based on acryloyldimethyltaurine | CLARIANT GMBH (DE) | 2004-07-22 | — | — | US | claimed |
| US-20040105825-A1 | Methods for producing foam from multiphase compositions | CLARIANT GMBH | 2004-06-03 | — | — | US | claimed |
| CN-118355099-A | Hand dishwashing composition containing ethoxylated glycerides | 科莱恩国际有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-12023309-B2 | Enhanced delivery epinephrine compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-4261924-A | FUNGICIDES, BACTERICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| US-4185106-A | Pyridones as antidandruff agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-22 | — | — | US | disclosed |
| US-4180084-A | HAIR-CARE, ESPECIALLY SHAMPOO | CIBA-GEIGY CORPORATION (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141937-A1 | comprising comb copolymers based on acryloyldimethyltaurine | ATIC, PCNA, FEN1 | CYP1A2 1962/4885KDM4E 3877/4885AGTR1 4130/4885 |
| US-20080107617-A1 | Surfactant-containing cosmetic, dermatological and pharmaceutical agents | SGMS1, SUCLG1, SGMS2 | CYP1A2 2139/4885KDM4E 4522/4885AGTR1 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.